TABLE 2

Comparison of the profile of various compounds as inhibitors of human neutrophil migration (this study) with the reported pharmacology of these ligands at abnormal-CBD receptors and the orphan receptor GPR55

Compound	Inhibition of Neutrophil Migration	Abnormal-CBD Receptor	GPR55
Endogenous lipid mediators
Virodhamine	+++	++^a	++^b
NADA	++	++^a	N.D.
AEA	+++	+^a	++^b
2-AG	0	0^a	++^b
		++^c
ARA-S	Antagonist	Agonist^d	N.D.
		Antagonist^e
PEA	0	0^c	++^b
LPI	0	N.D.	++^f,^g
Phytocannabinoids and related ligands
(−)-CBD	+++	+^a ++^c	++^b
	Partial agonist	Partial agonist	Antagonist
(+)-CBD	++	N.D.	N.D.
Abnormal-CBD	++	++^c	++^h
		+^a	+^b
O-1602	++	+ⁱ	++^h
			++^b
Δ⁹-THC	0	0^a,^c	++^b
Other
CP55940	++	0^a	++^b
SR141716A	Antagonist	Antagonist^a,^c	Partial agonist^j

The symbols represent the potency or affinity of compounds being in the picomolar range (+++), nanomolar range (++), micromolar range (+), or not determined (N.D.).
↵ a Begg et al. (2005).
↵ b Ryeberg et al. (2007).
↵ c Walter et al. (2003).
↵ d Millman et al. (2005).
↵ e Zhang et al. (2006).
↵ f Oka et al. (2007).
↵ g Oka et al. (2007) report that cannabinoid ligands do not activate GPR55.
↵ h Johns et al. (2007).
↵ i Járai et al. (1999).
↵ j Drmota et al. (2004).